Clinical Trial Search

Primary: Pathologic Complete Response Rate by Transurethral Resection of Bladder Tumor (TURBT) and Imaging Studies After Chemotherapy — 46 percentage of participants

Primary: Number of Participants That Achieved Complete Resolution of Subretinal Fluid on OCT Without Rescue Treatment — 16; 2 participants

Primary: Percent Change in Body Weight From Baseline to Week 12 — -1.1; -2.0; -2.8; -2.5 Percent change — p=0.031

Primary: Brief Social Phobia Scale(BSPS) — 44.0; 31.8; 31.8; 31.2 units on a scale — p=< 0.001

Primary: Absolute Change From Baseline in the Frequency of Migraine Attacks — -0.8; -1.0; -1.0 number of migraine attacks/participant

Primary: Gracely Box Intensity Rating Scale — 13.18; 14.43; 10.64; 13.00 units on a scale

Primary: Knee Score at 2 Years Post Operation — 91; 89 units on a scale

Primary: Change From Baseline to Endpoint in Mean Pain, Scored Daily on a on an 11-point (0-10) Numeric Rating Pain Scale (NRPS), Where 0 = no Pain and 10 = Worst Possible Pain…

Primary: Participants With At Least One Treatment-Emergent Adverse Event (TEAE) — 50 participants

Primary: Natural Logarithm Transformed Serum Intact Fibroblast Growth Factor (FGF-23) Levels at Week 12 Last Observation Carried Forward (LOCF) — 4.0089; 4.1210 pg/ml — p=0.3186

Primary: Proportion of Patients With Sterile Sputum Cultures — 59; 45 Participants

Primary: Number of Subjects Exhibiting Anti-motavizumab Antibodies — 2; 3; 0; 3 participants

Primary: Change in Immunization Status — 73; 4 participants — p=<0.001

Primary: Number of Patients Alive Without Disease Progression — 10 participants

Primary: Creatine Rephosphorylation Rate Post Exercise — 0.024; 0.029; 0.022; 0.029 pH per second — p=0.9133